VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2022 | The role of triplet therapy in men with metastatic castration sensitive prostate cancer

Gwenaëlle Gravis Mescam, MD, Institut Paoli Calmettes, Marseille, France, comments on the subset of patients with metastatic castration sensitive prostate cancer (mCSPC) who will benefit the most from the use of triplet therapy. The Phase III PEACE-1 trial (NCT01957436) established patients with low volume mCSPC had longer radiological progression-free survival (rPFS) when receiving abiraterone, prednisone and androgen deprivation therapy (ADT). The Phase III ARASENS trial (NCT02799602) additionally demonstrated darolutamide plus ADT and docetaxel to improve survival in patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter